{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:34:16Z","timestamp":1786995256580,"version":"build-2736575974"},"reference-count":164,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007185","name":"University of California Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007185","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014547","name":"Parker Institute for Cancer Immunotherapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014547","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.molmed.2026.07.012","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T04:31:40Z","timestamp":1786941100000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging therapeutic opportunities targeting nonclassical MHC-I molecules"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9858-300X","authenticated-orcid":false,"given":"Yan-Ruide","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2026.07.012_bb0005","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","article-title":"Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells","volume":"175","author":"Andr\u00e9","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2026.07.012_bb0010","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s40425-019-0761-3","article-title":"Monalizumab: inhibiting the novel immune checkpoint NKG2A","volume":"7","author":"van Hall","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.molmed.2026.07.012_bb0015","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.cell.2018.10.028","article-title":"NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines","volume":"175","author":"van Montfoort","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2026.07.012_bb0020","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ccell.2023.01.001","article-title":"Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2026.07.012_bb0025","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3892\/ol.2014.2686","article-title":"Lesion human leukocyte antigen-F expression is associated with a poor prognosis in patients with hepatocellular carcinoma","volume":"9","author":"Xu","year":"2015","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.molmed.2026.07.012_bb0030","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.7150\/ijbs.56357","article-title":"Targeting HLA-F suppresses the proliferation of glioma cells via a reduction in hexokinase 2-dependent glycolysis","volume":"17","author":"Chen","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.molmed.2026.07.012_bb0035","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3389\/fimmu.2019.00964","article-title":"The emerging roles of human leukocyte antigen-F in immune modulation and viral infection","volume":"10","author":"Lin","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0040","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.4049\/jimmunol.1300081","article-title":"HLA-F and MHC class I open conformers are ligands for NK cell Ig-like receptors","volume":"191","author":"Goodridge","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0045","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1038\/s44321-024-00106-1","article-title":"LILRB1-HLA-G axis defines a checkpoint driving natural killer cell exhaustion in tuberculosis","volume":"16","author":"Wang","year":"2024","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.molmed.2026.07.012_bb0050","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.trecan.2021.01.004","article-title":"HLA-G\/LILRBs: a cancer immunotherapy challenge","volume":"7","author":"Carosella","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.molmed.2026.07.012_bb0055","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1158\/1538-7445.AM2025-3132","article-title":"Innovative development of IMB-201, an anti-HLA-G antibody-drug conjugate (ADC), for enhanced tumor immunotherapy","volume":"85","author":"Kang","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2026.07.012_bb0060","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ymthe.2022.11.019","article-title":"Mucosal-associated invariant T cells for cancer immunotherapy","volume":"31","author":"Li","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2026.07.012_bb0065","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1158\/1078-0432.CCR-18-3040","article-title":"Activated and exhausted MAIT cells foster disease progression and indicate poor outcome in hepatocellular carcinoma","volume":"25","author":"Duan","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2026.07.012_bb0070","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1158\/2159-8290.CD-19-0569","article-title":"MAIT cells promote tumor initiation, growth, and metastases via tumor MR1","volume":"10","author":"Yan","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.molmed.2026.07.012_bb0075","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s42003-024-05912-4","article-title":"Delivery of loaded MR1 monomer results in efficient ligand exchange to host MR1 and subsequent MR1T cell activation","volume":"7","author":"Kulicke","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0080","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.3390\/cancers14112749","article-title":"Targeting immunosuppressive tumor-associated macrophages using innate T cells for enhanced antitumor reactivity","volume":"14","author":"Li","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.molmed.2026.07.012_bb0085","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/ni.3523","article-title":"CD1a on Langerhans cells controls inflammatory skin disease","volume":"17","author":"Kim","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0090","doi-asserted-by":"crossref","first-page":"7535","DOI":"10.1038\/s41467-022-35071-1","article-title":"CD1a promotes systemic manifestations of skin inflammation","volume":"13","author":"Hardman","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2026.07.012_bb0095","doi-asserted-by":"crossref","DOI":"10.1128\/iai.00380-24","article-title":"Establishment of CD1b-restricted immunity to lipid antigens in the pulmonary response to Mycobacterium tuberculosis infection","volume":"92","author":"Harris","year":"2024","journal-title":"Infect. Immun."},{"key":"10.1016\/j.molmed.2026.07.012_bb0100","article-title":"A conserved human CD4+ T cell subset recognizing the mycobacterial adjuvant trehalose monomycolate","volume":"135","author":"Sakai","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2026.07.012_bb0105","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1038\/s41467-021-25223-0","article-title":"Human T cells engineered with a leukemia lipid-specific TCR enables donor-unrestricted recognition of CD1c-expressing leukemia","volume":"12","author":"Consonni","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2026.07.012_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1614610","article-title":"A CD1c lipid agnostic T cell receptor bispecific engager redirects T cells against CD1c+ cells","volume":"16","author":"Szoke-Kovacs","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0115","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood.2022016201","article-title":"Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy","volume":"141","author":"Courtney","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2026.07.012_bb0120","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3389\/fimmu.2018.00367","article-title":"The role of natural killer T cells in cancer-a phenotypical and functional approach","volume":"9","author":"Krijgsman","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0125","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3389\/fimmu.2017.01178","article-title":"Natural killer T cells in cancer immunotherapy","volume":"8","author":"Nair","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0130","article-title":"Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy","volume":"2","author":"Li","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.molmed.2026.07.012_bb0135","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1600-0854.2005.00272.x","article-title":"The cellular pathway of CD1e in immature and maturing dendritic cells","volume":"6","author":"Ang\u00e9nieux","year":"2005","journal-title":"Traffic"},{"key":"10.1016\/j.molmed.2026.07.012_bb0140","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00251-016-0939-5","article-title":"Structure and function of the non-classical major histocompatibility complex molecule MR1","volume":"68","author":"Krovi","year":"2016","journal-title":"Immunogenetics"},{"key":"10.1016\/j.molmed.2026.07.012_bb0145","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.3389\/fimmu.2019.01837","article-title":"Editorial: role of CD1- and MR1-restricted T cells in immunity and disease","volume":"10","author":"Iwabuchi","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0150","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/jimmun\/vkae068","article-title":"HLA-E\/peptide complexes differentially interact with NKG2A\/CD94 and T cell receptors","volume":"214","author":"Voogd","year":"2025","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0155","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.lungcan.2011.04.006","article-title":"HLA-F expression is a prognostic factor in patients with non-small-cell lung cancer","volume":"74","author":"Lin","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.molmed.2026.07.012_bb0160","article-title":"Biological characteristics of HLA-G and its role in solid organ transplantation","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2023.102351","article-title":"Molecular insights into metabolite antigen recognition by mucosal-associated invariant T cells","volume":"83","author":"Awad","year":"2023","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0170","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41590-020-0616-6","article-title":"The molecular basis underpinning the potency and specificity of MAIT cell antigens","volume":"21","author":"Awad","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0175","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00251-016-0931-0","article-title":"The CD1 family: serving lipid antigens to T cells since the Mesozoic era","volume":"68","author":"Zajonc","year":"2016","journal-title":"Immunogenetics"},{"key":"10.1016\/j.molmed.2026.07.012_bb0180","doi-asserted-by":"crossref","DOI":"10.4161\/onci.26491","article-title":"Role of non-classical MHC class I molecules in cancer immunosuppression","volume":"2","author":"Kochan","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.molmed.2026.07.012_bb0185","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.3389\/fimmu.2020.01685","article-title":"HLA-G neo-expression on tumors","volume":"11","author":"Loustau","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0190","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1182\/blood-2004-08-3335","article-title":"HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia","volume":"105","author":"N\u00fcckel","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2026.07.012_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1525924","article-title":"Association between human leukocyte antigen E expression and outcomes in solid tumors: a systematic review and meta-analysis","volume":"15","author":"Benitez Fuentes","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0200","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/bs.ai.2015.03.003","article-title":"Activation and function of iNKT and MAIT cells","volume":"127","author":"Chandra","year":"2015","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0205","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3389\/fimmu.2015.00302","article-title":"Role of innate T cells in anti-bacterial immunity","volume":"6","author":"Gao","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0210","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3389\/fimmu.2018.01478","article-title":"Insights into mucosal-associated invariant T cell biology from studies of invariant natural killer T cells","volume":"9","author":"Garner","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0215","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/s41590-023-01523-z","article-title":"HLA class I signal peptide polymorphism determines the level of CD94\/NKG2-HLA-E-mediated regulation of effector cell responses","volume":"24","author":"Lin","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0220","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.it.2022.03.002","article-title":"Antigen presentation by MHC-E: a putative target for vaccination?","volume":"43","author":"Voogd","year":"2022","journal-title":"Trends Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0225","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/352160","article-title":"HLA-E: a novel player for histocompatibility","volume":"2014","author":"Kraemer","year":"2014","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.molmed.2026.07.012_bb0230","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1084\/jem.20020797","article-title":"A signal peptide derived from hsp60 binds HLA-E and interferes with CD94\/NKG2A recognition","volume":"196","author":"Micha\u00eblsson","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2026.07.012_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fviro.2022.1026452","article-title":"Overview of how HCMV manipulation of host cell intracellular trafficking networks can promote productive infection","volume":"2","author":"Mosher","year":"2022","journal-title":"Front. Virol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0240","article-title":"The immune response to human cytomegalovirus: impact of age, co-morbidities and the significance of anti-viral activity assessment","volume":"380","author":"Jackson","year":"2025","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"key":"10.1016\/j.molmed.2026.07.012_bb0245","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01206-24","article-title":"Regulation of the cell surface expression of classical and non-classical MHC proteins by the human cytomegalovirus UL40 and rhesus cytomegalovirus Rh67 proteins","volume":"98","author":"Brackenridge","year":"2024","journal-title":"J. Virol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0250","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1172\/JCI77440","article-title":"IL-12-producing monocytes and HLA-E control HCMV-driven NKG2C+ NK cell expansion","volume":"124","author":"R\u00f6lle","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2026.07.012_bb0255","article-title":"Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy","volume":"10","author":"Chen","year":"2023","journal-title":"Front. Med."},{"key":"10.1016\/j.molmed.2026.07.012_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.humimm.2025.111652","article-title":"HLA-E gene polymorphism and expression in colorectal cancer patients","volume":"87","author":"Dhouioui","year":"2026","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0265","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1438235","article-title":"Immune microenvironment in papillary thyroid carcinoma: roles of immune cells and checkpoints in disease progression and therapeutic implications","volume":"15","author":"Zheng","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0270","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1038\/s41467-024-47581-1","article-title":"Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks","volume":"15","author":"Qu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2026.07.012_bb0275","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.22.00227","article-title":"COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung cancer","volume":"40","author":"Herbst","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0280","article-title":"CD8+ T cell targeting of tumor antigens presented by HLA-E","volume":"10","author":"Iyer","year":"2026","journal-title":"Sci. Adv."},{"key":"10.1016\/j.molmed.2026.07.012_bb0285","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/35869","article-title":"HLA-E binds to natural killer cell receptors CD94\/NKG2A, B and C","volume":"391","author":"Braud","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2026.07.012_bb0290","doi-asserted-by":"crossref","first-page":"305","DOI":"10.4049\/jimmunol.162.1.305","article-title":"Specific recognition of HLA-E, but not classical, HLA class I molecules by soluble CD94\/NKG2A and NK cells","volume":"162","author":"Brooks","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0295","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41577-025-01218-6","article-title":"Targeting MHC-E as a new strategy for vaccines and immunotherapeutics","volume":"26","author":"Fr\u00fch","year":"2026","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0300","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1016\/j.ymthe.2024.11.035","article-title":"Managing allorejection in off-the-shelf CAR-engineered cell therapies","volume":"33","author":"Li","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2026.07.012_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.09.010","article-title":"Targeting HLA-E-overexpressing cancers with a NKG2A\/C switch receptor","volume":"6","author":"S\u00e6tersmoen","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.molmed.2026.07.012_bb0310","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1038\/s41467-023-40220-1","article-title":"High-throughput characterization of HLA-E-presented CD94\/NKG2x ligands reveals peptides which modulate NK cell activation","volume":"14","author":"Huisman","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2026.07.012_bb0315","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/907092","article-title":"The emerging role of HLA-E-restricted CD8+ T lymphocytes in the adaptive immune response to pathogens and tumors","volume":"2010","author":"Pietra","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0320","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.4049\/jimmunol.1000078","article-title":"HLA-F complex without peptide binds to MHC class I protein in the open conformer form","volume":"184","author":"Goodridge","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0325","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.immuni.2017.06.002","article-title":"Human leukocyte antigen F presents peptides and regulates immunity through interactions with NK cell receptors","volume":"46","author":"Dulberger","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.molmed.2026.07.012_bb0330","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/ni.3513","article-title":"Open conformers of HLA-F are high-affinity ligands of the activating NK-cell receptor KIR3DS1","volume":"17","author":"Garcia-Beltran","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163297","article-title":"HLA-F and MHC-I open conformers bind natural killer cell Ig-like receptor KIR3DS1","volume":"11","author":"Burian","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2026.07.012_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2025.1661511","article-title":"Emerging roles of natural killer cell ligands-HLA-E, HLA-F, HLA-G, MICA, and MICB-in in vitro fertilization outcomes","volume":"16","author":"Chaaithanya","year":"2025","journal-title":"Front. Genet."},{"key":"10.1016\/j.molmed.2026.07.012_bb0345","doi-asserted-by":"crossref","first-page":"8222","DOI":"10.7150\/thno.116951","article-title":"Inhibitory leukocyte immunoglobulin-like receptors, subfamily B (LILRBs) in human diseases: structure, roles, mechanisms, and clinical applications","volume":"15","author":"Zhang","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.molmed.2026.07.012_bb0350","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.it.2007.01.002","article-title":"Open conformers: the hidden face of MHC-I molecules","volume":"28","author":"Arosa","year":"2007","journal-title":"Trends Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0355","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.3390\/cancers16244266","article-title":"Targeting of non-classical human leukocyte antigens as novel therapeutic strategies in cancer","volume":"16","author":"Fuentes","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.molmed.2026.07.012_bb0360","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00018-010-0581-6","article-title":"HLA-G in organ transplantation: towards clinical applications","volume":"68","author":"Deschaseaux","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.molmed.2026.07.012_bb0365","article-title":"Allosteric disulfide control of ligand binding and endocytosis of KIR2DL4, the natural killer cell receptor for HLA-G","author":"Rajagopalan","year":"2026","journal-title":"bioRxiv"},{"key":"10.1016\/j.molmed.2026.07.012_bb0370","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/ni.1890","article-title":"Antimicrobial activity of mucosal-associated invariant T cells","volume":"11","author":"Le Bourhis","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0375","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nature13160","article-title":"T-cell activation by transitory neo-antigens derived from distinct microbial pathways","volume":"509","author":"Corbett","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2026.07.012_bb0380","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature11605","article-title":"MR1 presents microbial vitamin B metabolites to MAIT cells","volume":"491","author":"Kjer-Nielsen","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2026.07.012_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2026.111470","article-title":"Allelic variation alters expression and antigen presentation of MR1 allomorphs","volume":"302","author":"Nelson","year":"2026","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2026.07.012_bb0390","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1189\/jlb.4TA0815-391RR","article-title":"Human MAIT-cell responses to Escherichia coli: activation, cytokine production, proliferation, and cytotoxicity","volume":"100","author":"Dias","year":"2016","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0395","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/cbic.202000466","article-title":"The effects of 5-OP-RU stereochemistry on its stability and MAIT-MR1 axis","volume":"22","author":"Matsuoka","year":"2021","journal-title":"Chembiochem"},{"key":"10.1016\/j.molmed.2026.07.012_bb0400","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/s41590-019-0444-8","article-title":"The biology and functional importance of MAIT cells","volume":"20","author":"Godfrey","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0405","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230037","article-title":"Type I interferons drive MAIT cell functions against bacterial pneumonia","volume":"220","author":"L\u00f3pez-Rodr\u00edguez","year":"2023","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2026.07.012_bb0410","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41577-023-00934-1","article-title":"MR1 antigen presentation to MAIT cells and other MR1-restricted T cells","volume":"24","author":"McWilliam","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0415","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.tim.2025.03.011","article-title":"The microbiota shapes the life trajectory of mucosal-associated invariant T cells","volume":"33","author":"Li","year":"2025","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0420","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41577-019-0191-y","article-title":"Mucosal-associated invariant T cells and disease","volume":"19","author":"Toubal","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0425","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003685","article-title":"Activated but impaired IFN-\u03b3 production of mucosal-associated invariant T cells in patients with hepatocellular carcinoma","volume":"9","author":"Huang","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.molmed.2026.07.012_bb0430","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1016\/j.cell.2023.07.026","article-title":"Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin","volume":"186","author":"Ruf","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2026.07.012_bb0435","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1158\/2326-6066.CIR-20-0925","article-title":"Activating mucosal-associated invariant T cells induces a broad antitumor response","volume":"9","author":"Ruf","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.molmed.2026.07.012_bb0440","article-title":"Human MAIT cells endowed with HBV specificity are cytotoxic and migrate towards HBV-HCC while retaining antimicrobial functions","volume":"3","author":"Healy","year":"2021","journal-title":"JHEP Rep."},{"key":"10.1016\/j.molmed.2026.07.012_bb0445","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adi8954","article-title":"MAIT cells monitor intestinal dysbiosis and contribute to host protection during colitis","volume":"9","author":"El Morr","year":"2024","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0450","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1016\/j.celrep.2019.08.050","article-title":"TCR and inflammatory signals tune human MAIT cells to exert specific tissue repair and effector functions","volume":"28","author":"Leng","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.molmed.2026.07.012_bb0455","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1126\/science.aaw2719","article-title":"Microbial metabolites control the thymic development of mucosal-associated invariant T cells","volume":"366","author":"Legoux","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.molmed.2026.07.012_bb0460","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.immuni.2022.12.004","article-title":"Role of MR1-driven signals and amphiregulin on the recruitment and repair function of MAIT cells during skin wound healing","volume":"56","author":"du Halgouet","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.molmed.2026.07.012_bb0465","doi-asserted-by":"crossref","DOI":"10.1126\/science.aax6624","article-title":"MAIT cells are imprinted by the microbiota in early life and promote tissue repair","volume":"366","author":"Constantinides","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.molmed.2026.07.012_bb0470","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1432651","article-title":"Insights into the tissue repair features of MAIT cells","volume":"15","author":"Gao","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0475","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1038\/s41467-019-10198-w","article-title":"Diverse MR1-restricted T cells in mice and humans","volume":"10","author":"Koay","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2026.07.012_bb0480","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41590-019-0578-8","article-title":"Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1","volume":"21","author":"Crowther","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0485","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adn0126","article-title":"Nucleobase adducts bind MR1 and stimulate MR1-restricted T cells","volume":"9","author":"Vacchini","year":"2024","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0490","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1419528","article-title":"Conserved allomorphs of MR1 drive the specificity of MR1-restricted TCRs","volume":"14","author":"Cornforth","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0495","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1547664","article-title":"Molecular basis underpinning MR1 allomorph recognition by an MR1-restricted T cell receptor","volume":"16","author":"Suckling","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0500","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2414792121","article-title":"MR1 presents vitamin B6-related compounds for recognition by MR1-reactive T cells","volume":"121","author":"McInerney","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2026.07.012_bb0505","article-title":"MR1-ligand cross-linking identifies vitamin B6 metabolites as TCR-reactive antigens","volume":"5","author":"Schmidlin","year":"2025","journal-title":"Cell Rep. Methods"},{"key":"10.1016\/j.molmed.2026.07.012_bb0510","doi-asserted-by":"crossref","DOI":"10.1172\/JCI181895","article-title":"MHC-related protein 1-restricted recognition of cancer via a semi-invariant TCR-\u03b1 chain","volume":"135","author":"Dolton","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2026.07.012_bb0515","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1016\/j.cell.2023.08.022","article-title":"CD1 lipidomes reveal lipid-binding motifs and size-based antigen-display mechanisms","volume":"186","author":"Huang","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2026.07.012_bb0520","first-page":"36","article-title":"Emerging roles of CD1 and lipids in human health and disease","volume":"47","author":"Rossjohn","year":"2026","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0525","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3389\/fimmu.2015.00337","article-title":"Role of group 1 CD1-restricted T cells in infectious disease","volume":"6","author":"Siddiqui","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0530","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/imm.12912","article-title":"The versatility of the CD1 lipid antigen presentation pathway","volume":"154","author":"Chancellor","year":"2018","journal-title":"Immunology"},{"key":"10.1016\/j.molmed.2026.07.012_bb0535","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/ni.2790","article-title":"CD1a-autoreactive T cells recognize natural skin oils that function as headless antigens","volume":"15","author":"de Jong","year":"2014","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0540","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1084\/jem.20140410","article-title":"A novel self-lipid antigen targets human T cells against CD1c(+) leukemias","volume":"211","author":"Lepore","year":"2014","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2026.07.012_bb0545","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000228","article-title":"Recognition of lyso-phospholipids by human natural killer T lymphocytes","volume":"7","author":"Fox","year":"2009","journal-title":"PLoS Biol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0550","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1038\/emboj.2012.54","article-title":"Lysophospholipid presentation by CD1d and recognition by a human natural killer T-cell receptor","volume":"31","author":"L\u00f3pez-Sagaseta","year":"2012","journal-title":"EMBO J."},{"key":"10.1016\/j.molmed.2026.07.012_bb0555","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/eji.201041211","article-title":"High-frequency and adaptive-like dynamics of human CD1 self-reactive T cells","volume":"41","author":"de Lalla","year":"2011","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0560","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1084\/jem.20141505","article-title":"Bee venom processes human skin lipids for presentation by CD1a","volume":"212","author":"Bourgeois","year":"2015","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2026.07.012_bb0565","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jid.2021.03.033","article-title":"CD1-restricted T cells in inflammatory skin diseases","volume":"142","author":"Genardi","year":"2022","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0570","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1146\/annurev.immunol.23.021704.115742","article-title":"Toward an understanding of NKT cell biology: progress and paradoxes","volume":"23","author":"Kronenberg","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0575","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1146\/annurev.immunol.25.022106.141711","article-title":"The biology of NKT cells","volume":"25","author":"Bendelac","year":"2007","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0580","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ccell.2024.11.010","article-title":"Breaking the mold: unconventional T cells in cancer therapy","volume":"43","author":"Li","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2026.07.012_bb0585","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1084\/jem.20011908","article-title":"Distinct functional lineages of human V\u03b124 natural killer T cells","volume":"195","author":"Lee","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2026.07.012_bb0590","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.clim.2010.11.014","article-title":"Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy","volume":"138","author":"Yamasaki","year":"2011","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0595","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41587-024-02226-y","article-title":"Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method","volume":"43","author":"Li","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0600","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3389\/fimmu.2015.00316","article-title":"Type II NKT cells in inflammation, autoimmunity, microbial immunity, and cancer","volume":"6","author":"Marrero","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0605","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.4049\/jimmunol.1601399","article-title":"Type II NKT cells and their emerging role in health and disease","volume":"198","author":"Dhodapkar","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0610","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.3389\/fimmu.2018.02917","article-title":"Ig-like transcript 2 (ILT2) blockade and lenalidomide restore NK cell function in chronic lymphocytic leukemia","volume":"9","author":"Villa-\u00c1lvarez","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0615","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40364-020-00191-7","article-title":"Overexpressed immunoglobulin-like transcript (ILT) 4 in lung adenocarcinoma is correlated with immunosuppressive T cell subset infiltration and poor patient outcomes","volume":"8","author":"Li","year":"2020","journal-title":"Biomark. Res."},{"key":"10.1016\/j.molmed.2026.07.012_bb0620","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1186\/s12885-020-07113-8","article-title":"The immune-checkpoint HLA-G\/ILT4 is involved in the regulation of VEGF expression in clear cell renal cell carcinoma","volume":"20","author":"Garc\u00eda","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.molmed.2026.07.012_bb0625","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/bs.ai.2015.04.001","article-title":"HLA-G: an immune checkpoint molecule","volume":"127","author":"Carosella","year":"2015","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0630","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/1878-0261.12119","article-title":"Novel landscape of HLA-G isoforms expressed in clear cell renal cell carcinoma patients","volume":"11","author":"Tronik-Le Roux","year":"2017","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0635","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/eji.200738017","article-title":"Activation of invariant NKT cells enhances the innate immune response and improves the disease course in influenza A virus infection","volume":"38","author":"Ho","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0640","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13287-022-02787-2","article-title":"Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention","volume":"13","author":"Li","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.molmed.2026.07.012_bb0645","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.0818-9641.2004.01261.x","article-title":"NKT cells and viral immunity","volume":"82","author":"Van Dommelen","year":"2004","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0650","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/156652409787314534","article-title":"Natural killer T cells and autoimmune disease","volume":"9","author":"Wu","year":"2009","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.molmed.2026.07.012_bb0655","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.3390\/ijms24044084","article-title":"Graft-versus-host disease modulation by innate T cells","volume":"24","author":"Fang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2026.07.012_bb0660","article-title":"Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers","volume":"25","author":"Li","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.molmed.2026.07.012_bb0665","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41467-024-44905-z","article-title":"A phase 1\/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome","volume":"15","author":"Hammond","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2026.07.012_bb0670","doi-asserted-by":"crossref","first-page":"9287","DOI":"10.1038\/s41467-024-53657-9","article-title":"Protective effect of TCR-mediated MAIT cell activation during experimental autoimmune encephalomyelitis","volume":"15","author":"Walkenhorst","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2026.07.012_bb0675","doi-asserted-by":"crossref","first-page":"7372","DOI":"10.1038\/s41467-023-43269-0","article-title":"Mucosal-associated invariant T cells contribute to suppression of inflammatory myeloid cells in immune-mediated kidney disease","volume":"14","author":"Gnirck","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2026.07.012_bb0680","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/intimm\/dxh018","article-title":"Accumulation of Valpha7.2-Jalpha33 invariant T cells in human autoimmune inflammatory lesions in the nervous system","volume":"16","author":"Ill\u00e9s","year":"2004","journal-title":"Int. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0685","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/brain\/awq354","article-title":"CD161(high)CD8+T cells bear pathogenetic potential in multiple sclerosis","volume":"134","author":"Annibali","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.molmed.2026.07.012_bb0690","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13075-017-1257-5","article-title":"Activation status of mucosal-associated invariant T cells reflects disease activity and pathology of systemic lupus erythematosus","volume":"19","author":"Chiba","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.molmed.2026.07.012_bb0695","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.it.2007.08.002","article-title":"A closer look at CD1d molecules: new horizons in studying NKT cells","volume":"28","author":"Stronge","year":"2007","journal-title":"Trends Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0700","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.trecan.2025.03.001","article-title":"The clinical landscape of CAR-engineered unconventional T cells","volume":"11","author":"Li","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.molmed.2026.07.012_bb0705","article-title":"Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design","volume":"26","author":"Li","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.molmed.2026.07.012_bb0710","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.3390\/cells11091583","article-title":"An ex vivo 3D tumor microenvironment-mimicry culture to study TAM modulation of cancer immunotherapy","volume":"11","author":"Li","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.molmed.2026.07.012_bb0715","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1172\/JCI37869","article-title":"V\u03b124-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages","volume":"119","author":"Song","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2026.07.012_bb0720","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.188.Supp.127.39","article-title":"M2 macrophages express CD1d and are selectively targeted by NKT cells in tumors (127.39)","volume":"188","author":"Courtney","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2025.103742","article-title":"Protocol to profile tumor and microenvironment from ovarian cancer patient samples and evaluate cell-based therapy using in vitro killing assays","volume":"6","author":"Li","year":"2025","journal-title":"STAR Protoc."},{"key":"10.1016\/j.molmed.2026.07.012_bb0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100804","article-title":"Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells","volume":"6","author":"Li","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.molmed.2026.07.012_bb0735","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abn6563","article-title":"TCR-engineered iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells","volume":"7","author":"Delfanti","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0740","first-page":"1607","article-title":"CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms","volume":"5","author":"Zhou","year":"2024","journal-title":"Nat. Can."},{"key":"10.1016\/j.molmed.2026.07.012_bb0745","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-026-01629-3","article-title":"Engineering an in vivo charging station for CAR-redirected invariant natural killer T cells to enhance cancer therapy","author":"Li","year":"2026","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.molmed.2026.07.012_bb0750","first-page":"1054","article-title":"A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent antitumor response","volume":"1","author":"Lameris","year":"2020","journal-title":"Nat. Can."},{"key":"10.1016\/j.molmed.2026.07.012_bb0755","article-title":"A bispecific T cell engager recruits both type 1 NKT and V\u03b39V\u03b42-T cells for the treatment of CD1d-expressing hematological malignancies","volume":"4","author":"Lameris","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.molmed.2026.07.012_bb0760","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1182\/blood-2010-08-303339","article-title":"Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17\u2013secreting T cells","volume":"117","author":"Dusseaux","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2026.07.012_bb0765","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000054","article-title":"Stepwise development of MAIT cells in mouse and human","volume":"7","author":"Martin","year":"2009","journal-title":"PLoS Biol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0770","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3389\/fimmu.2019.00260","article-title":"Circulating mucosal-associated invariant T cells in a large cohort of healthy Chinese individuals from newborn to elderly","volume":"10","author":"Chen","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0775","doi-asserted-by":"crossref","first-page":"76274","DOI":"10.18632\/oncotarget.11187","article-title":"Clinical relevance of circulating mucosal-associated invariant T cell levels and their anti-cancer activity in patients with mucosal-associated cancer","volume":"7","author":"Won","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.molmed.2026.07.012_bb0780","article-title":"Human tumor-infiltrating MAIT cells display hallmarks of bacterial antigen recognition in colorectal cancer","volume":"1","author":"Li","year":"2020","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.molmed.2026.07.012_bb0785","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1007\/s00262-021-02939-y","article-title":"Exhaustion in tumor-infiltrating mucosal-associated invariant T (MAIT) cells from colon cancer patients","volume":"70","author":"Rodin","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.molmed.2026.07.012_bb0790","article-title":"Acetoacetate suppresses colon cancer via an MR1-MAIT axis","author":"Clay","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.molmed.2026.07.012_bb0795","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005902","article-title":"Clinicopathological and predictive value of MAIT cells in non-small cell lung cancer for immunotherapy","volume":"11","author":"Shi","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.molmed.2026.07.012_bb0800","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40164-025-00654-3","article-title":"Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer","volume":"14","author":"Lyu","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.molmed.2026.07.012_bb0805","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007340","article-title":"Phase 1\/2 study of monalizumab plus durvalumab in patients with advanced solid tumors","volume":"12","author":"Patel","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.molmed.2026.07.012_bb0810","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","article-title":"Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis","volume":"26","author":"Heczey","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2026.07.012_bb0815","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","article-title":"Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results","volume":"29","author":"Heczey","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2026.07.012_bb0820","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jtct.2023.12.072","article-title":"Off-the-shelf CD19-specific CAR-NKT cells in patients with relapsed or refractory B-cell malignancies","volume":"30","author":"Ramos","year":"2024","journal-title":"Transplant. Cell. Ther."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491426001826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491426001826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:53:11Z","timestamp":1786992791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491426001826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":164,"alternative-id":["S1471491426001826"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2026.07.012","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging therapeutic opportunities targeting nonclassical MHC-I molecules","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2026.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}